{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:40Z","timestamp":1790698900529,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past two decades, ribavirin has been an integral component of treatment for hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection, where it has been shown to improve the efficacy of (pegylated) interferon. However, because of treatment\u2010limiting side effects and its additive toxicity with interferon, the search for interferon\u2010 and ribavirin\u2010free regimens has been underway. The recent approvals of all\u2010oral direct acting antivirals (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s) have revolutionized the <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> therapeutic landscape, and initially it was expected that the role of ribavirin with <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> regimens would be eliminated. On the contrary, what we have witnessed is that ribavirin retains an important role in the optimal treatment of some subgroups of patients, particularly those that historically have been considered the most difficult to cure. Fortunately, it has also been recognized that the safety profile of ribavirin is improved when co\u2010administered with all\u2010oral <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> combinations in the absence of interferon. Despite the antiviral mechanism of action of ribavirin being poorly understood, we now have a range of novel insights into the potential role of ribavirin in all\u2010oral <jats:styled-content style=\"fixed-case\">DAA HCV<\/jats:styled-content> treatment and greater insight into the antiviral mechanism by which it continues to provide clinical benefit for defined patient groups.<\/jats:p>","DOI":"10.1111\/liv.13212","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T19:28:20Z","timestamp":1475177300000},"page":"5-18","source":"Crossref","is-referenced-by-count":89,"title":["Ribavirin revisited in the era of direct\u2010acting antiviral therapy for hepatitis C virus infection"],"prefix":"10.1111","volume":"37","author":[{"given":"Jordan J.","family":"Feld","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease Toronto General Hospital  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Mount Sinai Beth Israel  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Johns Hopkins University  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[{"name":"Texas Liver Institute University of Texas Health Science Center  San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tatsch","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Pawlotsky","sequence":"additional","affiliation":[{"name":"Department of Virology National Reference Center for Viral Hepatitis B, C and Delta H\u00f4pital Henri Mondor Universit\u00e9 Paris\u2010Est  Cr\u00e9teil France"},{"name":"INSERM U955  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60934-8"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.051"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-12-199512150-00001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80550-1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80225-X"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit074"},{"key":"e_1_2_7_14_1","unstructured":"REBETOL US Prescribing Information Initial approval1998.https:\/\/www.merck.com\/product\/usa\/pi_circulars\/r\/rebetol\/rebetol_pi.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_15_1","unstructured":"MODERIBA US Prescribing Information Initial approval2002.http:\/\/www.rxabbvie.com\/pdf\/moderiba_PI.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_7_19_1","unstructured":"HARVONI US Prescribing Information Initial approval2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205834s000lbl.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_20_1","unstructured":"HARVONI EU Summary of Product Characteristics Initial approval2014.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27826"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_7_24_1","unstructured":"AASLD\u2010IDSA Guidance Panel.HCV guidance: recommendations for testing managing and treating hepatitis C.http:\/\/www.hcvguidelines.org\/. Accessed August 25 2015."},{"key":"e_1_2_7_25_1","first-page":"755A","article-title":"Effectiveness of 12 or 24\u00a0week LDV\/SOF and 12\u00a0week LDV\/SOF + RBV in treatment\u2010experienced patients with cirrhotic, genotype 1 Hepatitis C: real\u2010world experience from the TRIO Network (poster presentation)","volume":"62","author":"Curry MP","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30976-4"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_7_29_1","unstructured":"VIEKIRA PAK US Prescribing Information Initial approval2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_30_1","unstructured":"VIEKIRAX EU Summary of Product Characteristics Initial approval2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003839\/WC500183997.pdf. Accessed August 25 2016."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.005"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30168-9"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30158-6"},{"key":"e_1_2_7_38_1","first-page":"229A","article-title":"An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with grazoprevir\/elbasvir (oral presentation)","volume":"62","author":"Jacobson IM","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_39_1","first-page":"556","article-title":"The combination of grazoprevir and elbasvir \u00b1 RBV is highly effective for the treatment of GT1a\u2010infected patients (poster presentation)","volume":"62","author":"Thompson AJ","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_40_1","first-page":"1393","article-title":"Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection (late\u2010breaking poster presentation)","volume":"62","author":"Jacobson IM","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_41_1","first-page":"555","article-title":"High efficacy of the combination HCV regimen grazoprevir and elbasvir for 8 or 12\u00a0weeks with or without ribavirin in treatment\u2010naive, noncirrhotic HCV GT1b\u2013infected patients: an integrated analysis (poster presentation)","volume":"62","author":"Serfaty L","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30149-5"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30003-9"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28446"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30015-5"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.519"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91129-R"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"issue":"1","key":"e_1_2_7_53_1","first-page":"742A","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir with or without ribavirin for patients with post\u2010transplant HCV recurrence","volume":"62","author":"Mantry P","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_54_1","first-page":"LB\u20104","article-title":"Safety and efficacy of new DAA\u2010based therapy for hepatitis C post\u2010transplant: interval results from the HCV\u2010TARGET longitudinal, observational study","volume":"60","author":"Brown RS","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_55_1","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30103-3","article-title":"The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large french prospective multicentric ANRS CO23 CUPILT cohort","volume":"62","author":"Coilly A","year":"2015","journal-title":"J Hepatol"},{"key":"e_1_2_7_56_1","unstructured":"University of Liverpool HEP Drug Interactions.http:\/\/www.hep-druginteractions.org\/. Accessed August 25 2016."},{"key":"e_1_2_7_57_1","first-page":"716","article-title":"RUBY\u2010I: ombitasvir\/paritaprevir\/ritonavir + dasabuvir +\/\u2010 ribavirin in non\u2010cirrhotic HCV genotype 1\u2010infected patients with severe renal impairment or end\u2010stage renal disease","volume":"62","author":"Pockros P","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31088-6"},{"key":"e_1_2_7_61_1","unstructured":"ClinicalTrials.gov Identifier NCT02487199 Ombitasvir\/paritaprevir\/ritonavir with or without dasabuvir in adults with genotype 1a or genotype 4 chronic hepatitis C virus (HCV) infection with severe kidney impairment or end stage kidney disease.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02487199?term=ombitasvir%2bRUBY%26rank=2. Accessed August 25 2016."},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31089-8"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"e_1_2_7_66_1","unstructured":"clinicaltrials.gov.A two part open\u2010label study to evaluate the safety and effectiveness of ABT\u2010450\/r\/ABT\u2010267 or ABT\u2010450\/r\/ABT\u2010267 and ABT\u2010333 given with or without a drug called ribavirin in people with both hepatitis C virus genotype 1 or 4 infection and human immunodeficiency virus type 1 infection (TURQUOISE\u2010I).2015;2015."},{"key":"e_1_2_7_67_1","first-page":"306A","article-title":"Once daily sofosbuvir (GS\u20107977) plus ribavirin\u00a0in patients with\u00a0HCV genotypes 1,2, and 3: the ELECTRON trial","volume":"56","author":"Gane E","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"issue":"2","key":"e_1_2_7_69_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0168-8278(16)01539-7","article-title":"All\u2010oral treatment with daclatasvir plus sofosbuvir\u00a0\u00b1 ribavirin in HCV genotype 3\u2010infected patients with advanced fibrosis or cirrhosis: an analysis of ALLY\u20103 and ALLY\u20103+ (poster presentation)","volume":"64","author":"Kowdley K","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_7_70_1","first-page":"225","article-title":"<br \/>Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program (oral presentation)","volume":"62","author":"Welzel TM","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_72_1","first-page":"337","article-title":"SURVEYOR\u2010II: high SVR4 rates achieved with the next generation NS3\/4A protease inhibitor ABT\u2010493 and NS5A inhibitor ABT\u2010530 in non\u2010cirrhotic treatment\u2010na\u00efve and treatment\u2010experienced patients with HCV genotype 3 infection","volume":"62","author":"Kwo P","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_73_1","first-page":"339","article-title":"SURVEYOR\u2010II: high SVR4 rates achieved with the next generation NS3\/4A protease inhibitor ABT\u2010493 and NS5A inhibitor ABT\u2010530 in non\u2010cirrhotic treatment\u2010na\u00efve and treatment\u2010experienced patients with HCV genotype 2 infection","volume":"62","author":"Wyles D","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00629-2"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30974-0"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30070-2"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.007"},{"key":"e_1_2_7_80_1","first-page":"1145A","article-title":"Safety of ABT\u2010450\/ritonavir\/ombitasvir + dasabuvir with or without ribavirin in HCV genotype 1\u2010infected patients: results from phase 2 and 3 trials","volume":"60","author":"Fried M","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27724"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32672"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.17.8074-8081.2001"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20253"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.064"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100349200"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27092"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111085598"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02778-12"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03153"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27186"},{"key":"e_1_2_7_93_1","first-page":"200A","article-title":"Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study","volume":"60","author":"Reddy KR","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30154-9"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T17:29:42Z","timestamp":1696181382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1111\/liv.13212"],"URL":"https:\/\/doi.org\/10.1111\/liv.13212","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]}}}